Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III norursodeoxycholic acid versus placebo in primary sclerosing cholangitis
2016-003367-19Phase 3Active
- Sponsor
- Dr. Falk Pharma GmbH
- Start
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Primary Sclerosing Cholangitis (PSC) comparing norursodeoxycholic acid with placebo (2 arms). Primary endpoint: Partial normalization of serum alkaline phosphatase and no worsening of disease stage by Ludwig stage. Started Jun 2017; status: active.
02
Drugs
norursodeoxycholic acid
03
Conditions
Primary Sclerosing Cholangitis (PSC)
Beyond the preview
Go deeper on 2016-003367-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003367-19.